Results 131 to 140 of about 355,535 (359)
Low ICU Admission and Excellent Outcomes in MIS‐C: A Swedish Study From an Open Society
Acta Paediatrica, EarlyView.ABSTRACT Aim During the COVID‐19 pandemic, Sweden chose a more open public health approach. A general concern was that this approach would affect the population negatively. We describe the Swedish national MIS‐C cohort and risk factors for severe disease defined as admission to the intensive care unit and cardiogenic shock.
Petra Król +13 more
wiley +1 more source
Opsoclonus‐Myoclonus: Not Always Paraneoplastic
Movement Disorders Clinical Practice, EarlyView.
Fernanda Lustosa Cabral Gomez +4 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post +4 more
wiley +1 more source
Risk Stratification for Sudden Cardiac Death In Patients With Non-ischemic Dilated Cardiomyopathy [PDF]
, 2005 Non ischemic dilated cardiomyopathy (NIDCM) is a disorder of myocardium. It has varying etiologies. Albeit the varying etiologies of this heart muscle disorder, it presents with symptoms of heart failure, and rarely as sudden cardiac death (SCD ...
Ghosh, Joydeep +3 more
core +1 more source
BJU International, EarlyView.Background Neurogenic bladder is defined as a dysfunction of the bladder resulting from damage to the central or peripheral nervous systems. Its treatment is based on a progressive therapeutic escalation, rapidly involving invasive therapeutic procedures such as repeated intradetrusor injections and surgery.
Marie Buzzi +6 more
wiley +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
British Journal of Pharmacology, EarlyView.Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source
Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2015 BACKGROUND AND OBJECTIVE: Arrhythmia is considered as a leading cause of sudden death among patients with cardiac diseases. Since antioxidant agents play a pivotal role in cardiac protection, many of them are used in the form of medicinal plants in ...
N Shoja +3 more
doaj
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev +36 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy +10 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions. Background and Purpose Ventricular arrhythmias are a leading cause of death among patients with cardiovascular diseases and are associated with elevated ...
Felipe de Jesús Salazar‐Ramírez +13 more
wiley +1 more source